CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback